Time New York: Wed 13 Dec 11:42 am  |  Save 15% on H&R Block Online

  
caticonslite_bm_alt

OMEROS CORP (OMER) Downgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research downgraded shares of OMEROS CORP (OMER) from OUTPERFORM to NEUTRAL on March 19, 2015, with a target price of $28.00.

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

To get a free copy of the research report on OMEROS CORP (OMER), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com .

<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.